Envíe una solicitud o llame para programar una cita.
Norton Children’s Cancer Institute, affiliated with the UofL School of Medicine, offers chimeric antigen receptor (CAR) T-cell therapy for children and teens with fairly advanced and/or recurrent B-cell acute lymphoblastic leukemia (ALL). CAR T-cell therapy is a newer approach to cancer treatment that uses the body’s own immune cells to kill cancerous cells. Norton Children’s Cancer Institute is the only pediatric program in Kentucky offering CAR T-cell therapy.
CAR T-cell therapy was approved by the U.S. Food and Drug Administration (FDA) for treating relapsed B-cell ALL in 2017. At this time, CAR T-cell therapy is not used for other types of leukemia or childhood cancer, but research is ongoing to expand this therapy to other types of childhood cancer.
CAR T-cell therapy is an immunotherapy in which the body’s immune system is activated to fight off disease. CAR T-cell therapy teaches the body’s immune system to recognize and eliminate cancerous B-cells, which can help the body control the growth of cancer cells over time.
CAR T-cell therapy works as follows:
Children and teens who receive CAR T-cell therapy will continue to be monitored for side effects after therapy.
Norton Children’s Cancer Institute offers tisagenlecleucel, an FDA-approved CAR T-cell treatment. This course of treatment is offered to patients up to age 25 with B-cell precursor ALL refractory (meaning treatment is not responding) or in second or later relapse.
We are the first and only treatment center offering this course of treatment to pediatric patients in Kentucky.
Se recomienda a las familias preguntar acerca de los beneficios potenciales de la terapia celular desde el principio del proceso de tratamiento oncológico del niño. For CAR T-cell therapy, collecting cells from a patient before serious illness and/or intensive chemotherapy can help the therapy be as successful as possible.
Alrededor del 85% de los casos de LLA se tratan con éxito con quimioterapia estándar. Sin embargo, en el otro 15% de los casos, la quimioterapia funciona temporalmente o no funciona en absoluto. CAR T-cell therapy is not a treatment for newly diagnosed leukemia — only for patients whose ALL is not responding to chemotherapy and the disease may have returned after a bone marrow transplant.